

# First systematic study of deadly, antibiotic-resistant fungus reported

24 February 2017

The deadly fungus, *Candida auris*, which has been found in hospitals, is resistant to entire classes of antimicrobial drugs, limiting treatment options for those infected. First reported in 2009, the fungus has been linked to invasive infections in nine countries, including the United States, and has caused at least two hospital outbreaks involving more than 30 patients each. Now, in a first-of-its-kind study published in *Antimicrobial Agents and Chemotherapy*, microbiologists at Case Western Reserve University School of Medicine have provided previously uninvestigated details pertaining to *C. auris* drug resistance and growth patterns. Based on specimens collected from around the globe, the comprehensive study also provides evidence that a new investigational drug (SCY-078) may help to cure these infections.

"This emerging fungal species has started to infect patients globally, causing [invasive infections](#) that are associated with a high death rate," said Mahmoud Ghannoum, PhD, MBA, FIDSA, Professor and Director of the Center for Medical Mycology in the Department of Dermatology at Case Western Reserve School of Medicine, and University Hospitals Cleveland Medical Center. "It is multidrug-resistant, and some strains isolated from patients are resistant to all commercially available antifungal drugs. Multidrug-resistance used to be reported for bacteria only, and now we must add fungi to the list."

Ghannoum led the investigation of 16 strains of *C. auris* collected from infected patients in Germany, Japan, Korea, and India. The researchers tested the isolates against a battery of 11 drugs, belonging to different classes of antifungals, to identify drug concentrations that could combat [infection](#). While most samples proved at least partially resistant to drugs tested, low concentrations of an [investigational drug](#) (SCY-078) "severely distorted" the fungus and impaired its growth, providing an important step towards the development of this drug to treat *C.*

*auris* infections. Fungi exposed to the drug could not divide, suggesting it could halt infections or limit their spread. Ghannoum's study is the first to provide details related to the effects of the investigational drug on *C. auris*.

The fungus lurks on catheters in intensive care units, where it forms highly drug-resistant communities, or biofilms. Ghannoum's team exposed fungi in the laboratory to silicone surfaces mimicking catheters. Under high-powered microscopes, they found *C. auris* formed relatively thin biofilms that weakened when exposed to the investigational drug. The findings were strain-dependent, but suggest applicability for the new drug to combat catheter-associated infections in particular.

Previous studies have shown the drug is effective against other *Candida* species that cause catheter-associated infections, including *C. albicans* and *C. tropicalis*. Said Ghannoum, "This drug is especially promising because of its broad anti-*Candida* activity, including activity against drug-susceptible and resistant strains."

The study is also the first to report *C. auris* does not germinate and produce spores like other fungi, a surprise given its ability to rapidly spread in hospitals. The researchers also discovered only certain strains produce destructive enzymes that commonly help fungi establish infections in body tissue. Despite these apparent weaknesses, the fungus is able to maintain extreme drug-resistance and infect patients. According to the paper, the "multidrug-resistant phenotype of *C. auris* comes with a major fitness cost."

Ghannoum's research provides a foundation for clinical trials to further study the investigational drug and informs doctors desperate for new ways to treat infections caused by *C. auris*. Said Ghannoum, "Understanding the virulence of *C. auris* and showing that the investigational [drug](#) is

effective may lead to the development of new medications to combat this emerging health threat."

The Centers for Disease Control and Prevention is actively tracking *C. auris* infections. Said Ghannoum, "Eradication of *Candida auris* from hospitals is very difficult and in some cases has led to closing hospital wards." People staying in hospitals for extended periods of time are most at risk. Laboratory workers who identify the species in a patient sample are encouraged to contact state or local public health authorities, or [candidaauris@cdc.gov](mailto:candidaauris@cdc.gov).

**More information:** Emily Larkin et al, The Emerging: Characterization of Growth Phenotype, Virulence Factors, Antifungal Activity, and Effect of SCY-078, a Novel Glucan Synthesis Inhibitor, on Growth Morphology and Biofilm Formation, *Antimicrobial Agents and Chemotherapy* (2017).  
[DOI: 10.1128/AAC.02396-16](https://doi.org/10.1128/AAC.02396-16)

Provided by Case Western Reserve University  
APA citation: First systematic study of deadly, antibiotic-resistant fungus reported (2017, February 24) retrieved 12 May 2021 from <https://medicalxpress.com/news/2017-02-systematic-deadly-antibiotic-resistant-fungus.html>

*This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.*